Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.

Authors :: Sardeli C
Zarogoulidis P
Romanidis K
Oikonomou P
Sapalidis K
Huang H
Bai C
Hohenforst-Schmidt W
Tsakiridis K
Zaric B
Perin B
Ioannidis A
Baka S
Drevelegas K
Kosmidou M
Kosmidis C
Source :: Respiratory medicine case reports [Respir Med Case Rep] 2020 Oct 25; Vol. 31, pp. 101258. Date of Electronic Publication: 2020 Oct 25 (Print Publication: 2020).
Publication Year :: 2020
Abstract: Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.<br />Competing Interests: All authors declare no conflict of interest.<br /> (© 2020 The Author(s).)

Full Text Access

Tools